Hints and tips:
...Dave Fredrickson, executive vice-president of the oncology business unit at AstraZeneca, said if today’s version of the reforms stand, patients with rare conditions, who have benefited from the Orphan Drug...
...Dave Fredrickson, executive vice-president of the company’s oncology business unit, says that if the IRA had been in place in 2014 AstraZeneca may not have filed for approval and launched the drug Lynparza...
...David Fredrickson, AstraZeneca’s executive vice-president of oncology, said Enhertu had the potential to become a “multi-blockbuster” medicine by being transformative in treating different types of breast...
International Edition